Minerva Neurosciences Past Earnings Performance
Past criteria checks 0/6
Minerva Neurosciences has been growing earnings at an average annual rate of 12%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 60% per year.
Key information
12.0%
Earnings growth rate
18.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -60.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Minerva says FDA declined to accept marketing application for schizophrenia drug
Oct 17Minerva Neurosciences: Biotech On The Move
Aug 29Minerva stock rises on filing for FDA approval of schizophrenia therapy
Aug 22We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
Jun 22
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?
Jan 26Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Oct 02Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares
Mar 03What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition
Jan 27We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate
Dec 23
A Potential Trade Arises On Minerva
Dec 09A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns
Nov 18Minerva Neurosciences EPS beats by $0.03
Nov 02Revenue & Expenses Breakdown
How Minerva Neurosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 10 | 2 |
| 30 Jun 24 | 0 | -34 | 10 | 0 |
| 31 Mar 24 | 0 | -32 | 10 | 0 |
| 31 Dec 23 | 0 | -30 | 10 | 0 |
| 30 Sep 23 | 0 | -28 | 10 | 7 |
| 30 Jun 23 | 0 | -27 | 10 | 0 |
| 31 Mar 23 | 0 | -29 | 10 | 0 |
| 31 Dec 22 | 0 | -32 | 11 | 0 |
| 30 Sep 22 | 0 | -47 | 11 | 0 |
| 30 Jun 22 | 0 | -49 | 11 | 0 |
| 31 Mar 22 | 0 | -51 | 12 | 0 |
| 31 Dec 21 | 0 | -50 | 13 | 0 |
| 30 Sep 21 | 0 | -36 | 14 | 0 |
| 30 Jun 21 | 0 | -35 | 15 | 0 |
| 31 Mar 21 | 41 | 5 | 17 | -8 |
| 31 Dec 20 | 41 | 2 | 17 | 0 |
| 30 Sep 20 | 41 | -21 | 17 | 0 |
| 30 Jun 20 | 41 | -27 | 19 | 0 |
| 31 Mar 20 | 0 | -69 | 17 | -4 |
| 31 Dec 19 | 0 | -72 | 18 | 0 |
| 30 Sep 19 | 0 | -55 | 19 | 9 |
| 30 Jun 19 | 0 | -54 | 18 | 17 |
| 31 Mar 19 | 0 | -54 | 17 | 38 |
| 31 Dec 18 | 0 | -50 | 17 | 35 |
| 30 Sep 18 | 0 | -37 | 15 | 32 |
| 30 Jun 18 | 0 | -36 | 14 | 33 |
| 31 Mar 18 | 0 | -33 | 12 | 31 |
| 31 Dec 17 | 0 | -32 | 11 | 30 |
| 30 Sep 17 | 0 | -41 | 11 | 30 |
| 30 Jun 17 | 0 | -38 | 11 | 27 |
| 31 Mar 17 | 0 | -34 | 10 | 23 |
| 31 Dec 16 | 0 | -31 | 10 | 20 |
| 30 Sep 16 | 0 | -30 | 9 | 20 |
| 30 Jun 16 | 0 | -28 | 8 | 18 |
| 31 Mar 16 | 0 | -29 | 8 | 20 |
| 31 Dec 15 | 0 | -27 | 8 | 19 |
| 30 Sep 15 | 0 | -26 | 10 | 15 |
| 30 Jun 15 | 0 | -47 | 11 | 36 |
| 31 Mar 15 | 0 | -60 | 12 | 46 |
| 31 Dec 14 | 0 | -57 | 12 | 43 |
| 30 Sep 14 | 0 | -52 | 9 | 40 |
| 30 Jun 14 | 0 | -25 | 7 | 15 |
| 31 Mar 14 | 0 | -6 | 4 | 1 |
Quality Earnings: NERV is currently unprofitable.
Growing Profit Margin: NERV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NERV is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare NERV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: NERV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.